KRAS and cancer: Therapeutically human βGBP has been proven to strongly reduce human Kras-mut/TP53-mut colorectal cancer xenograft growth as a single agent11 and, as a single agent, to drive to apoptotic death a variety of cancer cells from solid tumours, including cells sourced from colon, pancreas, prostate and breast which bear Kras mutations and tumour suppressor deficiency.5